Stay updated with breaking news from Commercialization Agreement. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today said that they expect Leqembi sales to total JPY 56.5 billion...
/PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the first...
STOCKHOLM, Sweden I April 20, 2024 I BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic AB and Eisai Co., Ltd., have entered into a
Stockholm, Sweden, April 1, 2024 - BioArctic AB's partner Eisai announced today that Eisai has submitted a supplemental Biologics License Application for monthly lecanemab-irmb intravenous ...
WAKIX® Net Revenue of $168.4 Million for Fourth Quarter and $582.0 Million for Full Year 2023; Representing Growth of ~31% and ~33%, Respectively U.S. Food and Drug Administration Granted...